Head-to-head evidence
CT-996 vs elecoglipron
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Obesity
Shared mechanism: GLP-1 receptor · full Obesity pipeline
CT-996
Developed by Roche
NCT07081958 · Phase 2 · completed
The study randomized 352 participants to placebo or one of seven RO7795081 dosing regimens, with participants and investigators blinded. Its primary endpoint was the clinical measure of percent change in body weight at Week 30, but no results or statistical comparison have been posted, so the endpoint cannot yet be classified as met or missed.
Next expected readout: December 2026 · NCT06982131 (registry estimate)
elecoglipron
Developed by AstraZeneca
NCT06579092 · Phase 2 · completed
This randomised, triple-blind, placebo-controlled trial in 310 adults living with obesity or overweight reported a 10.5% reduction in body weight on elecoglipron 75 mg against 0.6% on placebo at 26 weeks. Percent weight change is the measure regulators accept as the primary efficacy endpoint in obesity.
Next expected readout: April 2028 · NCT07775404 (registry estimate)
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: CT-996's landscape · elecoglipron's landscape